Intestinal Inflammation Targets Cancer-Inducing Activity of the Microbiota
C. Jobin, E. Perez-Chanona, T. Abujamel, A. A. Fodor, T. O. Keku, J. M. Uronis, B. Dogan, Blake Campbell, J. C. Arthur, J. J. Hansen, K. W. Simpson, S. Tomkovich, M. Muhlbauer, Jayce Rhodes, Ashton Rogers, A. Stintzi, Tongqiang Fan
Abstract
Inflammation alters host physiology to promote cancer, as seen in colitis-associated colorectal cancer (CRC). Here we identify the intestinal microbiota as a target of inflammation that impacts the progression of CRC. High-throughput sequencing revealed that inflammation modifies gut microbial composition in colitis-susceptible interleukin-10-deficient (Il10−/−) mice. Monocolonization with the commensal Escherichia coli NC101 promoted invasive carcinoma in azoxymethane (AOM)-treated Il10−/− mice. Deletion of the polyketide synthase (pks) genotoxic island from E. coli NC101 decreased tumor multiplicity and invasion in AOM/Il10−/− mice, without altering intestinal inflammation. Mucosa-associated pks+ E. coli were found in a significantly high percentage of inflammatory bowel disease (IBD) and CRC patients. This suggests that in mice, colitis can promote tumorigenesis by altering microbial composition and inducing the expansion of microorganisms with genotoxic capabilities.